Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations

Acta Psychiatrica Scandinavica
A D StantD Wiersma

Abstract

To examine the cost-effectiveness of Hallucination focused Integrative Treatment (HIT) in patients with schizophrenia and a history of persistent auditory hallucinations. Costs, in and outside the health care sector, and outcomes were registered prospectively during a period of 18 months for patients who received the HIT programme and for patients in the care as usual (CAU) condition. The Positive and Negative Syndrome Scale (PANSS) was used as main outcome measure in the cost-effectiveness analysis. Bootstrap analyses provided additional information on the skewly distributed costs. Mean costs per patient in the HIT group (18,237 dollars) were lower than the mean costs per patient in the CAU group (21,436 dollars). Results of the PANSS were slightly in favour of the HIT group. There appears to be no significant cost-effectiveness advantage of the HIT programme over CAU. Additional analyses indicated that future application of the HIT programme will, in most cases, lead to a reduction of (non) medical costs.

References

May 1, 1992·Social Science & Medicine·M A Koopmanschap, B M van Ineveld
Oct 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·N TarrierC Barrowclough
Aug 1, 1995·Archives of General Psychiatry·W R McFarlaneJ Toran
Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Nov 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·V DruryF Macmillan
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·A M GrayJ Morris
Nov 14, 1997·Acta Psychiatrica Scandinavica·D WiersmaG Driessen
Dec 16, 1998·The British Journal of Psychiatry : the Journal of Mental Science·E KuipersC Hadley
May 8, 1995·Journal of Health Economics·M A KoopmanschapL van Roijen
Mar 29, 2000·Psychiatric Services : a Journal of the American Psychiatric Association·J S McCombsR Smith
Nov 23, 2000·Social Psychiatry and Psychiatric Epidemiology·Y J PijlD Wiersma
Mar 23, 2001·Acta Psychiatrica Scandinavica. Supplementum·M Knapp
Jan 31, 2002·The Journal of Clinical Psychiatry·M LewisS Frangou
Jun 28, 2002·Acta Psychiatrica Scandinavica·Martin KnappUNKNOWN EPSILON. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs
Jul 4, 2002·Psychiatric Services : a Journal of the American Psychiatric Association·Jack A Jenner

❮ Previous
Next ❯

Citations

May 17, 2005·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Gerard van de WilligeJack A Jenner
Jan 5, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Mark van der GaagDurk Wiersma
Apr 30, 2009·Schizophrenia Research·Hans Joachim SalizeStefan Priebe
Sep 9, 2004·Acta Psychiatrica Scandinavica·J SanjuanJ van Os
Nov 17, 2007·Acta Psychiatrica Scandinavica·A D StantD Wiersma
Oct 10, 2013·Journal of Marital and Family Therapy·Jacob D ChristensonHarvey H Hillin
Apr 10, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·A D StantD Wiersma
Feb 27, 2004·Acta Psychiatrica Scandinavica·D WiersmaG van de Willige
Dec 24, 2010·Clinical Schizophrenia & Related Psychoses·Kandi FelmetJohn W Kasckow

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.